Daily Discussion Thread for September 16, 2026

{"summary": "Author argues Nebius (NBIS) is deeply undervalued relative to its projected 2028 revenue, implying massive upside even at conservative multiples.", "reason": "The author provides a fundamental valuation thesis based on projected revenue growth and GAAP profitability, supported by a verbatim quote.", "ideas": [{"symbol": "NBIS", "direction": "long", "thesis": "Author argues NBIS is expected to reach $25B in annual revenue/ARR by 2028, and even at a conservative 10x sales multiple that implies a $250B market cap (~$900/share before dilution). At the current 42x TTM sales multiple applied to $25B revenue, the stock would be worth roughly $1T (~$4,000/share), though the author acknowledges a 40x+ sales multiple in 2028 is extremely aggressive. A bonus catalyst is that NBIS is expected to be GAAP profitable in 2028. Main risk is that the aggressive multiple assumption may not hold.", "thesis_short": "NBIS undervalued vs 2028 revenue projections", "quote": "NBIS is expected to do $25B in annual revenue/ARR by 2028.", "confidence": 0.85, "sentiment": 0.9, "timeframe": "by 2028"}], "model": "gemini-3.1-flash-lite", "failure_count": 0, "verified": true, "extraction_model": "deepseek-flash"}